References
- Eddy AA, Symons JM. Nephrotic syndrome in childhood. Lancet. 2003;362:629–639
- Schwaderer P, Knüppel T, Konrad M, et al. Clinical course and NPHS2 analysis in patients with late steroid-resistant nephrotic syndrome. Pediatr Nephrol. 2008;23:251–256
- Kim JS, Bellew CA, Silverstein DM, et al. High incidence of initial and late steroid resistance in childhood nephrotic syndrome. Kidney Int. 2005;68:1275–1281
- Weber S, Gribouval O, Esquivel EL, et al. NPHS2 mutation analysis shows genetic heterogeneity of steroid-resistant nephrotic syndrome and low post-transplant recurrence. Kidney Int. 2004;66:571–579
- Ruf RG, Lichtenberger A, Karle SM, et al. Patients with mutations in NPHS2 (podocin) do not respond to standard steroid treatment of nephrotic syndrome. J Am Soc Nephrol. 2004;15:722–732
- Caridi G, Bertelli R, Di Duca M, et al. Broadening the spectrum of diseases related to podocin mutations. J Am Soc Nephrol. 2003;14:1278–1286
- Qi R, Li W. FK506 inhibits the mice glomerular mesangial cells proliferation by affecting the transforming growth factor β and Smads signal pathways. Ren Fail. 2014;36:589–592
- Tory K, Menyhárd DK, Woerner S, et al. Mutation-dependent recessive inheritance of NPHS2-associated steroid-resistant nephrotic syndrome. Nat Genet. 2014;46:299–304
- Ren-Qi, Zhao H. Losartan reverses glomerular podocytes injury induced by AngII via stabilizing the expression of GLUT1. Mol Biol Reports. 2013;40:6295–6301
- Yu M, Ren Q. Role of nephrin phosphorylation inducted by dexamethasone and angiotensin II in podocytes. Mol Biol Reports. 2014;41:3591–3595
- Bouchireb K, Boyer O, Gribouval O, et al. NPHS2 mutations in steroid-resistant nephrotic syndrome: A mutation update and the associated phenotypic spectrum. Hum Mutat. 2014;35:178–186
- Koziell A, Grech V, Hussain S, et al. Genotype/phenotype correlations of NPHS1 and NPHS2 mutations in nephrotic syndrome advocate a functional inter-relationship in glomerular filtration. Hum Mol Genet. 2002;11:379–388
- Bouchireb K, Boyer O, Gribouval O, et al. NPHS2 mutations in steroid-resistant nephrotic syndrome: A mutation update and the associated phenotypic spectrum. Hum Mutat. 2014;35:178–186
- Ren-Qi. Role of bad in podocyte apoptosis induced by puromycin aminonucleoside. Transplant Proc. 2013;45:569–573
- McKenzie LM, Hendrickson SL, Briggs WA, et al. NPHS2 variation in sporadic focal segmental glomerulosclerosis. J Am Soc Nephrol. 2007;18:2987–2995
- Wang G, Lai FM, Lai KB, et al. Intra-renal and urinary mRNA expression of podocyte-associated molecules for the estimation of glomerular podocyte loss. Ren Fail. 2010;32:372–379
- Komatsuda A, Wakui H, Maki N, et al. Analysis of mutations in alpha-actinin 4 and podocin genes of patients with chronic renal failure due to sporadic focal segmental glomerulosclerosis. Ren Fail. 2003;25:87–93
- Gbadegesin RA, Winn MP, Smoyer WE. Genetic testing in nephrotic syndrome—challenges and opportunities. Nat Rev Nephrol. 2013;9:179–184
- Efstratiadis G, Memmos D, Tsiaousis G, et al. Strumpell's disease in a family with hereditary focal segmental glomerulosclerosis. Ren Fail. 2006;28:351–354
- Kerti A, Csohány R, Szabó A, et al. NPHS2 p.V290M mutation in late-onset steroid-resistant nephritic syndrome. Pediatr Nephrol. 2013;28:751–757
- Bouchireb K, Boyer O, Gribouval O, et al. NPHS2 mutations in steroid-resistant nephrotic syndrome: A mutation update and the associated phenotypic spectrum. Hum Mutat. 2014;35:178–186
- Stojnev S, Pejcic M, Dolicanin Z, et al. Challenges of genomics and proteomics in nephrology. Ren Fail. 2009;31:765–772